American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
-
Am J Health Syst Pharm · Sep 2013
ReviewPertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
The pharmacology, pharmacokinetics, clinical efficacy, safety, and administration of pertuzumab in patients with metastatic human epidermal growth factor receptor type 2 (HER2)-positive breast cancer are reviewed. ⋯ Pertuzumab, a novel HER2 dimerization inhibitor, has been shown to be effective in the treatment of metastatic HER2-positive breast cancer when used in combination with trastuzumab and docetaxel and is recommended for first-line therapy.
-
Am J Health Syst Pharm · Sep 2013
Effect of a pharmacist on timing of postintubation sedative and analgesic use in trauma resuscitations.
Pharmacists' impact in reducing the time interval from intubation to sedative and analgesic use during trauma patient resuscitations is investigated. ⋯ The presence of a pharmacist during RSI procedures was associated with decreased times to postintubation sedative and analgesic use, indicating that pharmacist participation in trauma-resuscitation responses can facilitate appropriate drug therapy.
-
Am J Health Syst Pharm · Sep 2013
ReviewIntravenous acetylcysteine for indications other than acetaminophen overdose.
The use of intravenous acetylcysteine for off-label indications, specifically non-acetaminophen-induced acute liver failure (NAI-ALF), severe alcoholic hepatitis, and contrast-induced nephropathy (CIN), is reviewed. ⋯ Data regarding the use of i.v. acetylcysteine for the treatment of NAI-ALF and severe alcoholic hepatitis and in the prevention of CIN are inconclusive, though some evidence supports its use in certain populations.
-
Am J Health Syst Pharm · Sep 2013
Observational StudyClinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients.
The safety of converting kidney transplant recipients on brand-name tacrolimus to generic tacrolimus during hospitalization was evaluated. ⋯ Substitution of a generic formulation of tacrolimus for the innovator product during hospitalization of kidney transplant recipients was safely implemented. Tacrolimus dosage adjustments were common throughout the transitions of care, regardless of the formulation used.